001     292120
005     20250814110727.0
024 7 _ |a 10.1016/j.ejca.2024.114255
|2 doi
024 7 _ |a pmid:39111207
|2 pmid
024 7 _ |a 0014-2964
|2 ISSN
024 7 _ |a 0959-8049
|2 ISSN
024 7 _ |a 1879-0852
|2 ISSN
024 7 _ |a (1990)
|2 ISSN
024 7 _ |a 1879-2995
|2 ISSN
024 7 _ |a (1965)
|2 ISSN
037 _ _ |a DKFZ-2024-01619
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Brinker, Titus
|0 P:(DE-He78)1e33961c8780aca9b76d776d1fdc1ebb
|b 0
|e First author
|u dkfz
245 _ _ |a Evaluation of a medical student-delivered smoking prevention program utilizing a face-aging mobile app for secondary schools in Germany: The Education Against Tobacco cluster-randomized controlled trial.
260 _ _ |a Amsterdam [u.a.]
|c 2024
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1723122807_31772
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C140#LA:C120#
520 _ _ |a To reduce smoking uptake in adolescents, the medical students' network Education Against Tobacco (EAT) has developed a school-based intervention involving a face-aging mobile app (Smokerface).A two-arm cluster-randomized controlled trial was conducted, evaluating the 2016 EAT intervention, which employed the mobile app Smokerface and which was delivered by medical students. Schools were randomized to intervention or control group. Surveys were conducted at baseline (pre-intervention) and at 9, 16, and 24 months post-intervention via paper & pencil questionnaires. The primary outcome was the difference in within-group changes in smoking prevalence between intervention and control group at 24 months.Overall, 144 German secondary schools comprising 11,286 pupils participated in the baseline survey, of which 100 schools participated in the baseline and at least one of the follow-up surveys, yielding 7437 pupils in the analysis sample. After 24 months, smoking prevalence was numerically lower in the intervention group compared to control group (12.9 % vs. 14.3 %); however, between-group differences in change in smoking prevalence between baseline and 24-months follow-up (OR=0.83, 95 %-CI: 0.64-1.09) were not statistically significant (p = 0.176). Intention to start smoking among baseline non-smokers declined non-significantly in the intervention group (p = 0.064), and remained essentially unchanged in the control group, but between-group differences in changes at the 24-months follow-up (OR=0.88, 0.64-1.21) were not statistically significant (p = 0.417).While a trend towards beneficial effects of the intervention regarding smoking prevalence as well as intention to start smoking among baseline non-smokers was observed, our smoking prevention trial demonstrated no significant effect of the intervention.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Prevention
|2 Other
650 _ 7 |a Schools
|2 Other
650 _ 7 |a Smoking
|2 Other
650 _ 7 |a Smoking prevention
|2 Other
650 _ 7 |a Tobacco prevention
|2 Other
700 1 _ |a Krieghoff-Henning, Eva I
|0 P:(DE-He78)8e2078af783ff2be822e7799c43bc86a
|b 1
|u dkfz
700 1 _ |a Suhre, Janina L
|b 2
700 1 _ |a Silchmüller, Marc Phillipp
|b 3
700 1 _ |a Divizieva, Evgenia
|b 4
700 1 _ |a Wilhelm, Jilada
|b 5
700 1 _ |a Hillebrand, Gabriel
|b 6
700 1 _ |a Haney, Ailís C
|b 7
700 1 _ |a Srivastava, Aayushi
|b 8
700 1 _ |a Haney, Caelán M
|b 9
700 1 _ |a Seeger, Werner
|b 10
700 1 _ |a Penka, Dominik
|b 11
700 1 _ |a Gall, Henning
|b 12
700 1 _ |a Gaim, Benedikt
|b 13
700 1 _ |a Glisic, Lazar
|b 14
700 1 _ |a Stark, Tobias
|b 15
700 1 _ |a Swoboda, Susanne M
|b 16
700 1 _ |a Baumermann, Sonja
|b 17
700 1 _ |a Brieske, Christian M
|b 18
700 1 _ |a Jakob, Lena
|b 19
700 1 _ |a Fahrner, Hannah Maria
|b 20
700 1 _ |a Anhuef, Ole
|b 21
700 1 _ |a Schmidt, Selina Marisa
|b 22
700 1 _ |a Alfitian, Jonas
|b 23
700 1 _ |a Taha, Lava
|b 24
700 1 _ |a Beißwenger, Hanna
|b 25
700 1 _ |a Groneberg, David A
|b 26
700 1 _ |a Thomas, Roger E
|b 27
700 1 _ |a Fröhling, Stefan
|0 P:(DE-He78)f0144d171d26dbedb67c9db1df35629d
|b 28
700 1 _ |a von Kalle, Christof
|b 29
700 1 _ |a Baudson, Tanja Gabriele
|b 30
700 1 _ |a Buslaff, Fabian
|b 31
700 1 _ |a Mons, Ute
|0 P:(DE-He78)1b59582b6c05ac4e57aa8b90dd9667f9
|b 32
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.ejca.2024.114255
|g Vol. 209, p. 114255 -
|0 PERI:(DE-600)1468190-0
|p 114255
|t European journal of cancer
|v 209
|y 2024
|x 0014-2964
856 4 _ |u https://inrepo02.dkfz.de/record/292120/files/1-s2.0-S0959804924009110-main.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/292120/files/1-s2.0-S0959804924009110-main.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:292120
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)1e33961c8780aca9b76d776d1fdc1ebb
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)8e2078af783ff2be822e7799c43bc86a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 28
|6 P:(DE-He78)f0144d171d26dbedb67c9db1df35629d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 32
|6 P:(DE-He78)1b59582b6c05ac4e57aa8b90dd9667f9
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2024
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J CANCER : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J CANCER : 2022
|d 2023-10-21
920 2 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 0
920 1 _ |0 I:(DE-He78)C140-20160331
|k C140
|l NWG Digitale Biomarker in der Onkologie
|x 0
920 1 _ |0 I:(DE-He78)B340-20160331
|k B340
|l Translationale Medizinische Onkologie
|x 1
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 2
920 0 _ |0 I:(DE-He78)C140-20160331
|k C140
|l NWG Digitale Biomarker in der Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C140-20160331
980 _ _ |a I:(DE-He78)B340-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21